Outcomes of 4-factor Prothrombin Complex Concentrate in Patients With Liver Disease and Nonvitamin K Antagonist-Related Coagulopathy: A Retrospective Study

The administration of 4-factor prothrombin complex concentrate (4F-PCC) has expanded beyond its Food and Drug Administration (FDA)-approved indication for the emergent reversal of vitamin K antagonists (VKAs). Therefore, this study aimed to evaluate the risks and benefits associated with the expande...

Descripción completa

Detalles Bibliográficos
Autores principales: Dodhiawala, Paarth B., Pribyl, Kyle, Larson, Jared, Vakayil, Victor, Chandrashekar, Malavika, Lord, Amanda, Welbig, Julie, Zantek, Nicole D., Martin, David, Harmon, James V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Manuscript
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10475228/
https://www.ncbi.nlm.nih.gov/pubmed/37649304
http://dx.doi.org/10.1177/10760296231198038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10475228/
https://www.ncbi.nlm.nih.gov/pubmed/37649304
http://dx.doi.org/10.1177/10760296231198038

Ejemplares similares